Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that, despite the patent expiry of key antibiotics in the next ten years, the community-acquired pneumonia drug market will be supported by increasing drug resistance and the uptake of new and recently launched products. The new Pharmacor study entitled Community-Acquired Pneumonia lists Pfizer's Zithromax, Abbott's Biaxin/Klacid, Roche's Rocephin, and Johnson & Johnson's Levaquin as major antibiotics that will face generic competition.

The study also finds that drug sales in the highly saturated, increasingly competitive market will decline slightly from more than $1.2 billion in 2003 to approximately $1.1 billion in 2013.

"The community-acquired pneumonia market will face intense negative drivers including the patent expiry of key products, efforts to limit prescribing, and market saturation," said John Lebbos, M.D., analyst at Decision Resources. "However, growing concern over drug resistance in the community will drive the uptake of new agents in the fluoroquinolone and ketolide classes, limiting overall sales decline. Market share is set to change significantly during the next ten years as branded agents replace products nearing the end of their patent life."

About Community-Acquired Pneumonia

Community-acquired pneumonia refers to a serious infection of the lungs that is acquired outside of a hospital or long term care facility. It is one of the most severe community-acquired respiratory infections and is associated with a relatively high rate of hospitalization. Overall, pneumonia is a major source of morbidity and mortality. If not treated properly, community acquired pneumonia can result in significant complications including sepsis and respiratory failure.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

U.S. and European Patent Expiry of Pfizer's Norvasc Will Constrain the Hypertension Drug Market

View Now